Research
Molecular
Promising candidates such as danuglipron and lotiglipron were discontinued due to hepatotoxicity.
Practitioners should be aware of safety concerns associated with certain GLP-1 receptor agonists.
StrongSupportsmedium confidence
Conversely, promising candidates such as danuglipron and lotiglipron were discontinued due to hepatotoxicity.
Why this rating
The statement is based on the development status of clinical candidates.
Source
Oral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies
Héctor Iván Saldívar-Cerón et al. · Scientia Pharmaceutica · 2025
reviewCited 9×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →